Trading Report: Today, Lenox Wealth Advisors Inc. Reached $223,000 position of Merck & Co. (MRK)

Today, Lenox Wealth Advisors Inc. Reached $223,000 position  of Merck & Co. (MRK)

Lenox Wealth Advisors Inc. decreased its stake in shares of Merck & Co. (NYSE:MRK) by 3.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,576 shares of the company’s stock after selling 131 shares during the period. Lenox Wealth Advisors Inc.’s holdings in Merck & Co. were worth $223,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Logan Capital Management Inc. raised its stake in Merck & Co. by 21.0% in the first quarter. Logan Capital Management Inc. now owns 328,465 shares of the company’s stock valued at $17,380,000 after buying an additional 56,951 shares during the last quarter. Avalon Advisors LLC raised its stake in Merck & Co. by 1.1% in the first quarter. Avalon Advisors LLC now owns 522,566 shares of the company’s stock valued at $27,649,000 after buying an additional 5,754 shares during the last quarter. Cypress Capital Group raised its stake in Merck & Co. by 25.7% in the first quarter. Cypress Capital Group now owns 29,697 shares of the company’s stock valued at $1,571,000 after buying an additional 6,075 shares during the last quarter. Clear Harbor Asset Management LLC raised its stake in Merck & Co. by 93.2% in the first quarter. Clear Harbor Asset Management LLC now owns 85,740 shares of the company’s stock valued at $4,537,000 after buying an additional 41,370 shares during the last quarter. Finally, One Capital Management LLC raised its stake in Merck & Co. by 4.7% in the first quarter. One Capital Management LLC now owns 44,272 shares of the company’s stock valued at $2,342,000 after buying an additional 1,983 shares during the last quarter. Institutional investors and hedge funds own 73.25% of the company’s stock.

Shares of Merck & Co. (NYSE:MRK) traded up 0.92% during midday trading on Friday, reaching $62.21. 3,501,268 shares of the company traded hands. Merck & Co. has a 1-year low of $47.97 and a 1-year high of $65.46. The company has a market capitalization of $171.52 billion, a PE ratio of 31.77 and a beta of 0.76. The company has a 50 day moving average price of $61.63 and a 200 day moving average price of $60.02.

Merck & Co. (NYSE:MRK) last announced its quarterly earnings results on Tuesday, October 25th. The company reported $1.07 earnings per share for the quarter, topping the consensus estimate of $0.99 by $0.08. Merck & Co. had a net margin of 13.76% and a return on equity of 24.25%. The firm earned $10.50 billion during the quarter, compared to analysts’ expectations of $10.17 billion. During the same quarter in the prior year, the company earned $0.96 EPS. The company’s revenue was up 4.6% compared to the same quarter last year. On average, analysts expect that Merck & Co. will post $3.78 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, January 9th. Stockholders of record on Thursday, December 15th will be given a $0.47 dividend. This represents a $1.88 annualized dividend and a dividend yield of 3.02%. The ex-dividend date of this dividend is Tuesday, December 13th. This is a boost from Merck & Co.’s previous quarterly dividend of $0.46. Merck & Co.’s dividend payout ratio is presently 93.88%.

A number of research firms have recently weighed in on MRK. BMO Capital Markets reiterated a “market perform” rating and set a $62.00 target price on shares of Merck & Co. in a report on Tuesday, August 2nd. Credit Suisse Group AG upgraded shares of Merck & Co. from a “neutral” rating to an “outperform” rating and increased their target price for the stock from $62.00 to $73.00 in a report on Sunday, August 7th. Jefferies Group increased their target price on shares of Merck & Co. from $53.00 to $57.00 and gave the stock a “hold” rating in a report on Monday, August 8th. Deutsche Bank AG increased their target price on shares of Merck & Co. from $58.00 to $59.00 and gave the stock a “hold” rating in a report on Monday, August 8th. Finally, Piper Jaffray Cos. reiterated a “neutral” rating and set a $62.00 target price (up from $58.00) on shares of Merck & Co. in a report on Monday, August 8th. Thirteen equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $66.24.

In other news, Director Rochelle B. Lazarus sold 20,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 2nd. The shares were sold at an average price of $59.06, for a total value of $1,181,200.00. Following the completion of the sale, the director now owns 9,594 shares of the company’s stock, valued at approximately $566,621.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Adam H. Schechter sold 39,200 shares of the company’s stock in a transaction that occurred on Thursday, September 1st. The stock was sold at an average price of $62.61, for a total transaction of $2,454,312.00. Following the completion of the sale, the executive vice president now directly owns 39,200 shares of the company’s stock, valued at approximately $2,454,312. The disclosure for this sale can be found here. 0.05% of the stock is currently owned by insiders.

Merck & Co. Company Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Related posts

Leave a Comment